Table 1 Selected characteristics of the study population: 191 cases, 417 controls.
| Â | Cases | Controls |
|---|---|---|
Characteristic | n(%) | n(%) |
Matched variables | ||
   Age at diagnosis (years) | ||
<40 | 15(8%) | 20(5%) |
40-49 | 33(17%) | 94(22%) |
50-59 | 59(31%) | 113(27%) |
60-74 | 84(44%) | 190(46%) |
   Race/ethnicity | ||
White, non-Hispanic | 146(76%) | 326(78%) |
White, Hispanic | 7(4%) | 11(3%) |
Black | 19(10%) | 42(10%) |
Asian | 19(10%) | 38(9%) |
   Surgery year | ||
1985-1989 | 127(66%) | 278(67%) |
1990-1994 | 64(34%) | 139(33%) |
   Adjuvant tamoxifen | ||
No | 134(70%) | 281(67%) |
Yes | 57(30%) | 136(33%) |
Unmatched variables | ||
   Tumor size (cm) | ||
≤ 1.0 | 40(21%) | 128(31%) |
1.1-2.0 | 84(44%) | 187(45%) |
2.1-4.0 | 63(33%) | 96(23%) |
>4.0 | 4(2%) | 6(1%) |
   Tumor grade (differentiation)1 | ||
Well | 21(11%) | 123(29%) |
Moderate | 79(41%) | 182(44%) |
Poor | 91(48%) | 112(27%) |
   ER status from RT-PCR2 | ||
Positive | 145(76%) | 370(89%) |
Negative | 46(24%) | 47(11%) |
   PR status from RT-PCR2 | ||
Positive | 117(61%) | 324(78%) |
Negative | 74(39%) | 93(22%) |
   HER2 status from RT-PCR2 | ||
Positive | 33(17%) | 41(10%) |
Negative | 158(83%) | 376(90%) |
   HOXB13:IL17BR |  |  |
Low risk | 71(37%) | 222(53%) |
High risk | 120(63%) | 195(47%) |
   MGI |  |  |
Low risk | 51(27%) | 197(47%) |
High risk | 140(73%) | 220(53%) |
   MGI+HOXB13:IL17BR |  |  |
Low risk | 51(27%) | 197(47%) |
Intermediate risk | 50(26%) | 108(26%) |
High risk | 90(47%) | 112(27%) |
   BCI |  |  |
Low risk | 55(29%) | 222(53%) |
Intermediate risk | 54(28%) | 85(20%) |
High risk | 82(43%) | 110(26%) |